Monitoring Initial Response to Angiotensin-Converting

Citation Report

#	Article	IF	Citations
2	Mistaken conclusions. Heart, 2011, 97, 2090-2091.	1.2	1
3	Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. European Journal of Preventive Cardiology, 2012, 19, 1474-1485.	0.8	18
4	A Counterargument to Encounter Frequency and Target Achievement: Measurement Variability. Archives of Internal Medicine, 2012, 172, 374.	4.3	0
5	The IDEAL Study : Towards Personalized Drug Treatment of Hypertension. Therapie, 2012, 67, 195-204.	0.6	3
6	Ambulatory blood pressure monitoring in Australia. Journal of Hypertension, 2012, 30, 253-266.	0.3	109
7	Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. Journal of Translational Medicine, 2012, 10, 47.	1.8	22
8	Vaccine adjuvant formulations: A pharmaceutical perspective. Seminars in Immunology, 2013, 25, 130-145.	2.7	125
9	Criteria for monitoring tests were described: validity, responsiveness, detectability of long-term change, and practicality. Journal of Clinical Epidemiology, 2014, 67, 152-159.	2.4	12
10	Blood pressure pharmacogenomics. Journal of Hypertension, 2015, 33, 1142-1143.	0.3	9
11	Replacing the hypertension control paradigm with a strategy of cardiovascular risk reduction. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 17-22.	1.8	7
12	A decade of individual participant data meta-analyses: A review of current practice. Contemporary Clinical Trials, 2015, 45, 76-83.	0.8	97
13	Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. Journal of Human Hypertension, 2015, 29, 22-27.	1.0	14
14	Blood pressure targets in primary care. BMJ, The, 2016, 352, i813.	3.0	2
15	Variability in response to albuminuriaâ€‘lowering drugs: true or random?. British Journal of Clinical Pharmacology, 2017, 83, 1197-1204.	1.1	22
16	EARLY CRT MONITORING USING TIME-DOMAIN OPTICAL COHERENCE TOMOGRAPHY DOES NOT ADD TO VISUAL ACUITY FOR PREDICTING VISUAL LOSS IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL RANIBIZUMAB. Retina, 2017, 37, 509-514.	1.0	2
17	Incremental Benefits and Harms of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. JAMA Internal Medicine, 2018, 178, 755.	2.6	40
18	The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study. Upsala Journal of Medical Sciences, 2019, 124, 51-58.	0.4	3
19	Statistical methods for testing carryover effects: A mixed effects model approach. Contemporary Clinical Trials Communications, 2021, 22, 100711.	0.5	3

#	Article	IF	Citations
20	The potential for overdiagnosis and underdiagnosis because of blood pressure variability: a comparison of the 2017 ACC/AHA, 2018 ESC/ESH and 2019 NICE hypertension guidelines. Journal of Hypertension, 2021, 39, 236-242.	0.3	17
21	A Novel Methodological Framework for Detecting and Quantifying Overdiagnosis. SSRN Electronic Journal, 0, , .	0.4	0
22	A novel methodological framework was described for detecting and quantifying overdiagnosis. Journal of Clinical Epidemiology, 2022, 148, 146-159.	2.4	3
23	Hypertension Management and Prevention: The Devil is Ever in the Details of Targets. Annals of the Academy of Medicine, Singapore, 2017, 46, 364-366.	0.2	3
24	Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs. JAMA - Journal of the American Medical Association, 2023, 329, 1160.	3.8	15